Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SWOG Cancer Research Network
M.D. Anderson Cancer Center
University of Chicago
Regeneron Pharmaceuticals
Genmab
Genmab
Genmab
Novartis